Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROOF 301: Infigratinib vs Gemcitabine + Cisplatin in FGFR2-Positive Cholangiocarcinoma
NCT03773302Phase 3Terminated
- Sponsor
- QED Therapeutics
- Start
- Dec 2019
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 3 trial of infigratinib in cholangiocarcinoma (CCA), sponsored by QED Therapeutics. Started Dec 2019; status: terminated.
02
Drugs
infigratinib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT03773302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03773302.